About us

Empowering Protein Science

Absea, located in the vibrant Life Science Park of Beijing, is committed to cutting-edge protein research. Absea has established outstanding protein R&D and technology platforms. Today, Absea has built the world's largest high-throughput protein expression platform and soluble human protein repository, and develops monoclonal antibodies to target the entire proteome. As a driver of innovation, Absea is augmenting its expertise in protein biotechnology with the power of state-of-the-art AI and bioinformatics tools. With this unique skill set, Absea is emerging as a rising star in proteome science and actively expanding its services into in vitro diagnostics, life science research and biopharmaceuticals.

At Absea, we are committed to deliver protein products with unmatched quality, characterization depth, and manufacturing speed. We open untapped opportunities in protein research by fostering innovation, cooperation and exploration. A trusted collaborator of industrial and academic researchers across the globe, we strive to become a long-term partner for the world's leading labs, companies and service providers to empower science.

10000+

Human proteins produced
2000+

Custom mAb projects
600+

New proteins per month
200+

New antibodies per month

Where we work

Beijing site

Founded in 2001

Suzhou site

Founded in Mar 2020.

Main sites

Beijing
- R&D Center
- 5000m² protein production site
Suzhou
- Headquarter
- Business Center
Shanghai
- Business Center
- Sales

Who we are

Tao Chen

CEO of Absea

Learn More
- One of the inventors of human single domain antibodies; patent and platform were acquired by Harbour BioMed for USD 85 million
- Co-developer of the TIDE algorithm, one of the most popular tools for gene editing assessment (Brinkman, Chen et al., NAR 2014, >1600 citations, software licensed to Desktop Genetics Ltd)
- Developer of a bioinformatics model to design soluble human protein sequences
Wei Zhang

Founder and CSO of Absea

Learn More
- Graduated from the University of Cambridge under the tutelage of Peter Lachmann, Cesar Milstein (1984 Nobel Prize in Medicine) and Greg Winter (2018 Nobel Prize in Chemistry)
- Emeritus Professor of Immunology of Peking Union Medical College
- Over 30 years of experience and expertise in developing proteins and monoclonal antibodies for academic and industrial customers all over the world
- Founded Absea in 2001 and led the company to become the world's leading antigen-antibody development platform
- Lead Developer in more than 1000 mAb projects
Fan Liu

SAB chair of Absea

Learn More
- Professor of Structural Interactomics, Charité University of Medicine, Berlin
- Head of Interactomics Research Unit and Proteomics Core Facility, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP)
- ERC Investigator
- Developer of XlinkX, one of the most widely used cross-link search engines in structural proteomics (Liu et al., Nat Methods 2015, software licensed to Thermo Fisher Scientific)
- SAB member of VantAI
Frank Grosveld

Co-founder and SAB member of Absea

Learn More
- Professor of Cell Biology, Erasmus Medical Center, Netherlands
- Fellow of the Royal Society, UK
- Member of the Royal Netherlands Academy of Arts and Sciences (KNAW)
- Louis-Jeantet Prize for Medicine (one of the most prestigious awards for biomedical research)
- Spinoza Prize (highest scientific award of the Netherlands)
- SAB chair of Harbour Biomed

What we stand for

Our Promise

Thoroughly validated, high-quality products
Customized services and product design
Fast production at large scale

Our Approach

Mature manufacturing system
Integration of cutting-edge AI and proteomics technology
Interdisciplinary team of highly qualified experts

Our Mission

Advancing academic and industrial research
Generating high-quality antibodies for next-generation diagnostics
Developing new tools and reagents for proteomics and life sciences